Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

Author： Chalret du Rieu Quentin   Fouliard Sylvain   Jacquet-Bescond Anne   Robert Renata   Kloos Ioana   Depil Stéphane   Chatelut Etienne   Chenel Marylore  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.30, Iss.10, 2013-10, pp. : 2640-2653

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Histone deacetylase inhibitors in clinical development

By Rosato Roberto R   Grant Steven  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 1, 2004-01 ,pp. : 21-38

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 210-216

John Wiley & Sons Inc

Access to resources Recommend Favorite

Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

By Gimsing Peter  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 501-508

Informa Healthcare

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 6, 2011-06 ,pp. : 519-527

Bentham Science Publishers

Access to resources Recommend Favorite

Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application

By  

Current Drug Metabolism, Vol. 8, Iss. 4, 2007-05 ,pp. : 383-394

Bentham Science Publishers

Access to resources Recommend Favorite